Stereotactic Radiofrequency Ablation of Breast Cancer Liver Metastases: Short- and Long-Term Results with Predicting Factors for Survival.
Date
2021-08-01ICR Author
Author
Schullian, P
Johnston, E
Laimer, G
Putzer, D
Eberle, G
Scharll, Y
Ianetti-Hackl, C
Bale, R
Type
Journal Article
Metadata
Show full item recordAbstract
PURPOSE: To evaluate safety, local oncological control, long-term outcome and potential prognostic factors of stereotactic RFA (SRFA) for the treatment of BCLMs. METHODS: Between July 2003 and December 2019, 42 consecutive female patients with median age 54.0 years were treated with SRFA at our institution for 110 BCLMs in 48 ablation sessions. Median tumor size was 3.0 cm (0.8-9.0). Eighteen (42.9%) patients had extrahepatic metastasis at initial SRFA. RESULTS: Technical success rate was 100%, i.e., all coaxial needles were inserted with appropriate accuracy within 10 mm off plan and 107/110 (92.3%) BCLMs were successfully ablated at initial SRFA. Four Grade 1 (8.3%, 4/48) and one Grade 2 (2.1%, 1/48) complications occurred. No perioperative deaths occurred. Local recurrence developed in 8 of 110 tumors (7.3%). Overall survival (OS) rates of all patients at 1, 3, and 5 years from the date of the first SRFA were 84.1%, 49.3%, and 20.8% with a median OS of 32.3 months. Univariable cox regression analyses revealed age > 60 years and extrahepatic disease (without bone only metastases) as significant predictors of worse OS (p = 0.013 and 0.025, respectively). Size and number of metastases, hormone receptor status and time onset did not significantly affect OS after initial SRFA. CONCLUSIONS: SRFA is a safe, minimally invasive treatment option in the management of BCLMs, especially in younger patients without advanced extrahepatic metastasis, including those with large liver tumors.
Collections
Subject
Breast cancer liver metastasis
Radiofrequency ablation
Stereotaxy
Adult
Aged
Aged, 80 and over
Breast Neoplasms
Female
Humans
Liver
Liver Neoplasms
Middle Aged
Radiofrequency Ablation
Retrospective Studies
Survival Rate
Time
Tomography, X-Ray Computed
Treatment Outcome
Language
eng
Date accepted
2021-03-01
License start date
2021-08-01
Citation
Cardiovascular and Interventional Radiology, 2021, 44 (8), pp. 1184 - 1193
Publisher
SPRINGER